清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH2] in postmenopausal women with osteoporosis

特立帕肽 医学 骨质疏松症 安慰剂 耐受性 骨矿物 内科学 骨重建 股骨颈 泌尿科 甲状旁腺激素 不利影响 内分泌学 钙 病理 替代医学
作者
Kim Henriksen,J.R. Andersen,Bente J. Riis,N. Mehta,Roxanne Tavakkol,Peter Alexandersen,I. Byrjalsen,Ivo Valter,Bettina S. Nedergaard,Christence Stubbe Teglbjærg,W. Stern,Amy Sturmer,S. Mitta,Antonio Nino,Lorraine A. Fitzpatrick,Claus Christiansen,M.A. Karsdal
出处
期刊:Bone [Elsevier BV]
卷期号:53 (1): 160-166 被引量:53
标识
DOI:10.1016/j.bone.2012.11.045
摘要

Treatment of osteoporosis with subcutaneous (SC) injections of rhPTH(1-34) or rhPTH(1-84) is associated with significant improvements in BMD and reductions in osteoporotic fractures. However, subcutaneous injections can be associated with discomfort and thus deteriorating compliance.The UGL-OR1001 trial aimed to establish the efficacy and safety parameters of a novel oral tablet formulation of rhPTH(1-31)NH(2) and matching placebo tablets and open-label teriparatide positive control in postmenopausal women with osteoporosis.24 weeks of randomized, double-blind treatment with once daily doses of 5mg oral treatment or corresponding placebo, or open-label subcutaneous teriparatide.Women diagnosed with postmenopausal osteoporosis as detected by lumbar spine DXA, with an exclusion of those with prior treatment with bone active agents.Orally formulated recombinant human PTH(1-31)NH(2) and placebo, or open-label subcutaneous teriparatide as a positive control.The primary endpoint was to characterize the percent change from baseline in bone mineral density (BMD) at L1-L4 axial lumbar spine after 24 weeks in the rhPTH(1-31)NH(2) arm. Secondary and exploratory endpoints included safety and tolerability of the oral formulation, measurement of biochemical markers of bone turnover, and evaluation of the PK profile at first and last dose. The study was registered at ClinicalTrials.gov with the identifier: NCT01321723.The oral tablet formulation of rhPTH(1-31)NH(2) resulted in similar PK profiles at both timepoints with mean C(max) values similar to subcutaneous administration. In the rhPTH(1-31)NH(2) arm, a 2.2% increase in lumbar spine BMD was observed compared to baseline (p<0.001), while no change was observed in the placebo arm. Open-label teriparatide resulted in a 5.1% increase in LS BMD (p<0.001). In the oral PTH study arm, the bone formation marker osteocalcin was increased by 32%, 21% and 23% at Weeks 4, 12 and 24, respectively. There was no significant increase in the level of the bone resorption marker CTx-1.In summary, these data demonstrate that enteric-coated oral tablet formulation technology consistently generated robust levels of exposure of rhPTH(1-31)NH(2) leading to induction of bone formation without inducing bone resorption resulting in significantly increased levels of LS BMD. Few adverse events were observed, recommending this orally delivered drug candidate for further development.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
huan完成签到,获得积分10
2秒前
ssnwlp123完成签到,获得积分10
2秒前
BlueLe完成签到,获得积分10
3秒前
Zilaap完成签到,获得积分10
4秒前
CaptainMus完成签到,获得积分10
5秒前
端庄的如松完成签到,获得积分10
5秒前
皮卡皮卡皮卡丘完成签到,获得积分10
6秒前
Maestro_S的应助被科研通管家采纳,获得10
7秒前
null的应助被科研通管家采纳,获得10
8秒前
花开富贵完成签到,获得积分10
9秒前
luyu完成签到,获得积分10
9秒前
mayberichard完成签到,获得积分10
9秒前
热情善斓完成签到,获得积分10
10秒前
dianeil发布了新的文献求助10
10秒前
hh完成签到,获得积分10
12秒前
昊儿虫完成签到,获得积分10
12秒前
宝哥完成签到,获得积分10
12秒前
顺心雁开完成签到,获得积分10
15秒前
Cling5899完成签到,获得积分10
16秒前
bao完成签到,获得积分10
17秒前
小冯完成签到,获得积分10
21秒前
fomo完成签到,获得积分0
22秒前
坦率钢笔完成签到,获得积分10
23秒前
yuan完成签到,获得积分10
24秒前
精明开山完成签到,获得积分10
27秒前
刘沂卓完成签到,获得积分10
29秒前
suda完成签到,获得积分10
33秒前
怡然的千儿完成签到,获得积分10
36秒前
MIO完成签到,获得积分10
38秒前
美满的水卉完成签到,获得积分10
38秒前
是丹小朱呀完成签到,获得积分10
39秒前
夏月虚闲完成签到,获得积分10
40秒前
yuxuan1完成签到,获得积分10
41秒前
yuxuan完成签到,获得积分10
45秒前
cxf完成签到,获得积分10
48秒前
Asumita完成签到,获得积分10
54秒前
啵啵椰完成签到,获得积分10
1分钟前
简单代梅完成签到,获得积分10
1分钟前
1分钟前
顺利的雅旋完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185411
求助须知:如何正确求助?哪些是违规求助? 9574140
关于积分的说明 21834375
捐赠科研通 7782865
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558842
邀请新用户注册赠送积分活动 2481280